The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Nutrition and ExerciseNutrition and Exercise
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Mar 15, 2015

Dear Nelson, I appreciate you so much for your great helps in preventing HIV and give us nice consulting¡CCurrently we know Ibalizumab has been gotten the breakthrough and orphan drug designation for medications¡Ahowever¡Ait still need to be performed the Phase III clinical trials¡CDo you know when the drug can be approved by FDA to rescue so many HIV patients with multiple drug resistance?

Response from Mr. Vergel

Ibalizumab is a research monoclonal antibody that blocks one of the receptors on the CD4 cell. The salvage activist community has met with Taimed and its predecessor for the past 13 years that this product has been studied.

As you say, ibalizumab (IV) now has not only orphan drug designation but also breakthrough therapy designation. This is the first time that a HIV treatment has received orphan drug resignation. Both of these designations will help to get the drug approved more quickly due to a lower required number of patients to enroll for phase 3.

It is difficult for anyone to predict approval of a pre-phase 3 drug.

The company is currently meeting FDA requirements to proceed for accrual of their upcoming fast track phase 3.


Pls help...what ED drug can I take while on atripla...
Lexapro and HIV Meds

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint